newsfilter
← Latest News
ACCESS Newswire·

NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001

FDA feedback provides clear clinical path for NEO-001, the first obesity drug therapy focused on neuropharmacological and behavioral changes for sustainable weight loss Company plans to file an IND application for a Phase 1/2 clinical study anticipated